Edwards Lifesciences (EW) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.78
- EPS estimate
- $0.74
- EPS surprise
- +4.97%
- Revenue surprise
- +2.40%
- Revenue
- $1.7B
- Revenue estimate
- $1.7B
- Reported
- Jul 23, 2026
Edwards Lifesciences reported Q2 2026 results on July 23, 2026. Earnings per share were $0.78, ahead of the $0.74 estimate by 4.97%. Revenue was $1.7 billion, 2.40% above the $1.7 billion consensus. Compared with Q2 2025, EPS rose about 16% from $0.67 and revenue rose about 13% from $1.5 billion. EPS matched Q1 2026's $0.78, and the two quarters share the table's EPS high.
The longer record shows slow growth in earnings and firmer growth in sales. Annual EPS was $2.48 in 2022, $2.51 in 2023, $2.62 in 2024 and $2.56 in 2025. Quarterly revenue rose from $1.3 billion in 2022 to $1.7 billion in the latest quarter, the highest in the table. The first half of 2026 totals $1.56 per share, about 19% more than a year earlier. Over the last 20 quarters, Edwards beat EPS estimates 15 times. Its largest beat was 12.40%, in Q3 2025, and its largest miss was 6.99%, in Q4 2021.
Edwards reported Q3 between October 24 and October 30 in each of the past five years. That points to late October 2026 for the next report. It will show whether the first-half pace carries into the third quarter.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 23, 2026 | $0.74 | $0.78 | +4.97% | $1.7B | SEC |
| Q1 2026 | Apr 23, 2026 | $0.73 | $0.78 | +6.98% | $1.6B | SEC |
| Q4 2025 | Feb 10, 2026 | $0.62 | $0.58 | −6.36% | $1.6B | SEC |
| Q3 2025 | Oct 30, 2025 | $0.60 | $0.67 | +12.40% | $1.6B | SEC |
| Q2 2025 | Jul 24, 2025 | $0.62 | $0.67 | +7.42% | $1.5B | SEC |
| Q1 2025 | Apr 23, 2025 | $0.60 | $0.64 | +7.29% | $1.4B | SEC |
| Q4 2024 | Feb 11, 2025 | $0.55 | $0.59 | +7.14% | $1.4B | SEC |
| Q3 2024 | Oct 24, 2024 | $0.66 | $0.67 | +0.81% | $1.4B | SEC |
| Q2 2024 | Jul 24, 2024 | $0.69 | $0.70 | +0.82% | $1.6B | SEC |
| Q1 2024 | Apr 25, 2024 | $0.64 | $0.66 | +2.66% | $1.6B | SEC |
| Q4 2023 | Feb 6, 2024 | $0.64 | $0.64 | +0.42% | $1.5B | SEC |
| Q3 2023 | Oct 25, 2023 | $0.59 | $0.59 | −0.52% | $1.5B | SEC |
| Q2 2023 | Jul 26, 2023 | $0.65 | $0.66 | +1.88% | $1.5B | SEC |
| Q1 2023 | Apr 26, 2023 | $0.61 | $0.62 | +1.91% | $1.5B | SEC |
| Q4 2022 | Jan 31, 2023 | $0.62 | $0.64 | +3.90% | $1.3B | SEC |
| Q3 2022 | Oct 27, 2022 | $0.62 | $0.61 | −1.82% | $1.3B | SEC |
| Q2 2022 | Jul 28, 2022 | $0.64 | $0.63 | −1.62% | $1.4B | SEC |
| Q1 2022 | Apr 26, 2022 | $0.57 | $0.60 | +5.04% | $1.3B | SEC |
| Q4 2021 | Jan 26, 2022 | $0.55 | $0.51 | −6.99% | $1.3B | SEC |
| Q3 2021 | Oct 27, 2021 | $0.53 | $0.54 | +1.39% | $1.3B | SEC |
Quarterly revenue
Frequently asked questions
When did Edwards Lifesciences (EW) last report earnings?
Edwards Lifesciences last reported on Jul 23, 2026, covering fiscal Q2 2026.
Did EW beat earnings estimates?
Yes. Edwards Lifesciences reported EPS of $0.78 for Q2 2026 against a $0.74 estimate — a 4.97% beat.
How much revenue did EW report last quarter?
Edwards Lifesciences reported $1.7B in revenue for Q2 2026, against a consensus estimate of $1.7B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.